Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial

Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial

(2022) E Wesley Ely et al.   Lancet Respiratory Medicine

Steroid use in elderly critically ill COVID-19 patients

(2021) Christian Jung et al.   EUROPEAN RESPIRATORY JOURNAL

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial

(2021) Vincent C Marconi et al.   Lancet Respiratory Medicine

Dexamethasone in hospitalised coronavirus-19 patients not on intensive respiratory support

(2021) Kristina Crothers et al.   EUROPEAN RESPIRATORY JOURNAL

Remdesivir for the Treatment of Covid-19 — Preliminary Report

(2020) John H. Beigel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report

(2020)   NEW ENGLAND JOURNAL OF MEDICINE

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

(2020) Andre C. Kalil et al.   NEW ENGLAND JOURNAL OF MEDICINE

The role of dysregulated immune responses in COVID-19 pathogenesis

(2020) S Tahaghoghi-Hajghorbani et al.   VIRUS RESEARCH

Corticosteroids for Patients With Coronavirus Disease 2019 (COVID-19) With Different Disease Severity: A Meta-Analysis of Randomized Clinical Trials

(2020) Laura Pasin et al.   JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA

Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR)

(2015) Scott R. Evans et al.   CLINICAL INFECTIOUS DISEASES

Quantifying The Cost And Quality Of Life Implications Of Adverse Events Associated With Long-Term Oral Corticosteroid Use

(2015) D Tilden et al.   VALUE IN HEALTH